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Abstract: Background: Owing to restricted treatment options, 
Vancomycin-resistant Enterococci (VRE) was considered a 
prominent cause of nosocomial infections. This study was 
undertaken to evaluate the presence of Van-type and virulence 
determinants in the clinical isolates of E. faecium (Ent. 
faecium) in Shariati Hospital. Materials and Methods: A total 
of 150 Enterococcal isolates were surveyed. Antimicrobial 
susceptibility testing was performed by disc diffusion and E-
test as well as the genotypic method. The presence of virulence 
factors, including hyaluronidase (hyl), gelatinase (gelE), 
aggregation substance (asa1), and Enterococci surface protein 
(ESP) were identified by Polymerase chain reaction (PCR). 
Results: Overall, 66.67 percent (80/120) of VRE Ent. faecium 
strains were confirmed by the PCR method. The maximum 
number of isolates was from urine specimens (p < 0.05) and 
blood samples. Among the 80 VRE Ent. faecium isolates, 76 
isolates showed high-level resistance (MICs to Vancomycin 
32 > µg/ml) and carried a VanA phenotype (p < 0.05). In all 
the isolates, asa1, gelE, and ESP genes were identified in 14% 
(17/5), 26/3% (21/80), and 45% (36/80), respectively. E. Ent. 
faecium carried ESP at a significantly higher frequency 
presented in VRE strains (p < 0.001). The prevalence of hly 
determinants in the E. faecium was 20% (16) (P < 0.001). 
Conclusion: We, in our hospital, are faced with a high rate of 
VRE Ent. faecium isolates with a VanA-positive phenotype. 
With increasing resistance of the VRE strains to linezolid, we 
will encounter a serious challenge in treating VRE patients in 
future years. An interesting finding from the present study is 
that the spreading rates of ESP and hly among Ent. faecium 
isolates are higher. 
Key Words: Enterococcus faecium, Antibiotic resistance, 
Vancomycin-resistant enterococci, Virulence factors 
 
Introduction: 
Enterococci is considered as the second most common 
nosocomial (hospital-acquired) infection; particularly 
endocarditis, ureteric infections, bacteremia, endocarditis, and 
meningitis (1, 2). Many species are responsible for human 
disease; however, Enterococcus faecium represent more than 
90% of the clinical isolates (1). In recent years, Enterococcus 
faecium has dramatically increased and emerged as an 
important cause of the multidrug-resistant (MDR) 
Enterococcal infection (3). The acquired resistance to several 
important clinical antibiotics, such as the resistance to 
Vancomycin in the Enterococcus isolates, has been a particular 
concern (3). Moreover, the increasing resistance to 
Vancomycin, high-level penicillin-resistant (HLPR) and 
gentamicin-resistant, has recently emerged (4, 5). The 
emergence of resistance to quinupristin/dalfopristin, 
daptomycin, and linezolid as therapeutic and preventative 
options led to dramatic challenges in treating MDR 
enterococcal infections (5-7) . Five main types (VanA, B, D, 
E, and G) of Vancomycin-resistance have been described 
based on both the phenotypic and genotypic methods (7). The 
VanA-type is responsible for the high levels of inducible 
resistance to both vancomycin and teicoplanin, whereas the 
VanB-type, can only cause variable levels of resistance to 
Vancomycin (7). The VanC phenotype is characterized by low 
resistance to Vancomycin and teicoplanin susceptibility 
(7).  Both Enterococcus faecalis and Enterococcus faecium are 
adaptable pathogens involving some host-specific lineages(8). 
Strains from human adapted clonal complexes (CCs) is a well-
established hospital pathogen associated with outbreaks and 
characterized by resistance to various antibiotics, such as 
quinolones and ampicillin (ARE)(8). Also, it is associated with 
the presence of a putative pathogenicity island markers, 
comprising the enterococcal surface protein encoding gene 
(esp) and hyaluronidase gene (hyl), and the IS16 insertion 
element esp gene. Without prior knowledge of Van-genotype, 
an expensive drug is prescribed for treatment in hospitals. 
Therefore, determining the Van genotype and the rate of 
distribution in order to appropriately prescribe a treatment for 
the patients is essential. In addition, data of the virulence 
determinants, including hyaluronidase (hyl), gelatinase (gelE), 
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aggregation substance (asa1), and enterococcal surface protein 
(ESP) in the Enterococcus strains, in Ent. faecium is still 
limited (9). Therefore, the objective of the study was to 
evaluate the presence of Van-type and virulence determinants 
in clinical isolates of Ent. faecium in Shariati Hospital. 
Materials and Methods 
Strain collection 
The clinical and epidemiological features of the eighty 
Enterococcal-infected patients were documented. This cross-
sectional study was performed on 80 Ent. faecium isolates that 
were collected from patient samples urine (36), blood (18) and 
BAL10, wound (7), sputum (6), tissue (2), and abscess (1) in 
Shariati Hospital on 1 February 2016. All the patients in 
different parts of the hospital departments were sampled, 
including patients in the general intensive care unit (ICU), 
Bone Marrow unit, Hematopoietic Stem Cell Transplantation 
(HSCT), Nephrology unit, Outpatient, Digestive unit, 
Neonatal Intensive Care Unit (NICU), Rheumatology unit, 
Lung unit, Women Emergency, Glands unit, Urology unit, and 
the Oral and Maxillofacial Surgery unit (Table1). The isolates 
were confirmed and distinguished as Enterococcus spp by 
using routine microbiological methods; then, the PCR 
amplification of the D-alanine-D-alanine ligases determinants 
specific to E. faecium and E. faecalis were used to confirm the 
phenotypic characters (10). 
Antibiotic susceptibility testing 
AST (Antimicrobial susceptibility testing) was performed by 
the modified Kirby Bauer disc diffusion method based on the 
CLSI guidelines against conventional antibiotics to determine 
the minimum inhibitory concentration (MIC). Determination 
of MIC of teicoplanin and Vancomycin (Sigma Aldrich, 
Germany) for the E. faecium isolates was performed using the 
E test (bioMerieux) method according to the CLSI guidelines 
(11). The results of MIC were interpreted according to CLSI 
guidelines (11). 
 
Table 1: PCR primers and products for the detection of virulence genes 
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F:5'- GCACGCTATTACGAACTATGA -3' 





 Gelatinase  gelE 
F= 5'- TATGACAATGCTTTTTGGGAT -3' 





F= 5'- AGATTTCATCTTTGATTCTTGG -3' 
R=5'- AATTGATTCTTTAGCATCTGG -3' 
510 
Hyaluronidase hyl 
F=5'-  ACAGAAGAGCTGCAGGAAATG -3' 
R=5'-  GACTGACGTCCAAGTTTCCAA -3' 
276 
 
DNA Extraction and PCR 
Total DNA extraction was performed by the QIAamp DNA 
mini kits (QIAGEN, Germany). Extracting DNA from the 
fresh cultures was performed based on following the 
manufacturer’s instructions. PCR assay was used for the 
detection of the Van A, Van C, and Van B genes in the VRE 
strains described by Kariyama et al. VanA amplification was 
performed with the primers VanA Forward: 5'- 
AATACTGTTTGGGGGTTGCTC-3' and VanA Reverse: 5' – 
CTTTTTCCGGCTCGACTTCCT- 3' to yield a 734-bp 
fragment, while the van was amplified with the primers VanB 
Forward: 5'- CATCGTCCCCGAATTTCAAA- 3' and van R 
5'- GATGCGGAAGATACCGTGGCT- 3' to yield a 295-bp 
fragment, and Van C2/C3 F- 5' 
CGCAGGGACGGTGATTTT- 3' and C2/C3 Reverse: 5'- 
CGGGGAAGATGGCAGTAT- 3' to yield a 484-bp fragment. 
The presence of gelE, ESP, and asa1 genes specific for 
virulence determinants were confirmed by the PCR assay 
method as described by Vankerckhoven (2001)(12). Then, the 
PCR method with appropriate primers and cycling conditions 
was performed. The sequences of primers and annealing 
temperatures used in our study are presented in Table I. 
Statistical Analysis 
All the statistical analyses were done by the SPSS (version 18) 
software, SPSS Inc. 
Enterococci Isolates 
In this cross-sectional study, a total of 120 Ent. faecium 
isolates were collected from 13,100 samples over a period of 
one year from different clinical specimens by using 
biochemical methods. The rate of the infection was estimated 
to be 9.2%. Overall, 80 VRE Ent. faecium strains were 
confirmed by the PCR method. Of the 80 VRE isolates, the 
maximum number of isolates were from urine specimens 25 
(45%), blood samples (22. 5%), and other samples with low 
numbers, including BAL, wound, sputum, tissue, and abscess 
(Fig. 1). Twenty-seven (33/7%) VRE isolates were associated 
with the age group of people under 50 years old. Therefore, in 
the present study, the presence of VRE Ent. faecium isolates 
in patients of 50 years or older shower significantly higher 
prevalence (p < 0.05). The rate of the prevalence of VRE 
isolates was equal across sexes (40 strains were related to 
males and 40 were related to females). 
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Antimicrobial Susceptibility Testing  
VRE Ent. faecium isolates were tested for susceptibility to six 
antimicrobial agents using the disk diffusion method. The 
isolates revealed resistance to ampicillin (87%), gentamicin 56 
(83/5%), linezolid 18 (22/5% intermediate), penicillin 78 
(97/5%), Vancomycin (100%), and nitrofurantoin 4/34 
(11/8%). Among the 80 VRE Ent. faecium isolates, 76 isolates 
showed high level resistance to (MICs to vancomycin 32 > 
µg/ml) carried a VanA phenotype while 4 isolates revealed 
that MIC Vancomycin (4-512 µg/ml) harbored VanB 
phenotype. None of the VRE isolates carried the VanB and the 
VanA phenotypes. Nitrofurantoin was used only for 34 urine 
isolates and 11/8% of all the urine isolates showed in vitro 
resistance to it. None of the Enterococcus isolates had high-
level resistance to linezolid, but 22/5% intermediate resistance 
was observed in a number of isolates. The susceptibility 
patterns of Ent. faecium to antibiotics have been presented in 
Table 2. 
 
Fig. 2. Comparative frequency of VRE E. faecium isolates 
among different sources. 
Table 2: The susceptibility patterns of E. faecium to antibiotics 
MDR pattern Nit P GM/20 AM LZD V Department Age Sex Specimen Strain Reception code 
VRE - R R R S R ICU nerves 23 F Blood Ent.Facium 492704 
VRE - R R S S R CCU Heart 77 M BAL Ent.Facium 2195 
VRE - R R R S R CCU Heart 81 M BAL Ent.Facium 9675 
VRE - R R S S R CCU Heart 50 M BAL Ent.Facium 8202 
VRE - R R R S R ICU Heart 49 F Blood Ent.Facium 9938 
VRE - R R R S R General Internal 77 M Blood Ent.Facium 8158 
VRE - R R R S R Glands (medical 2) 97 M Tissue Ent.Facium 14089 
VRE - R R R S R Surgery room 55 M Tissue Ent.Facium 13782 
VRE S R R R S R Emergency Clinic 81 M Urine Ent.Facium 17716 
VRE - R S R S R POST HSCT 22 M BAL Ent.Facium 24617 
VRE - R R R S R Glands (medical 2) 47 M Wound Ent.Facium 24634 
VRE - R R S S R Internal ICU 55 M Sputum Ent.Facium 41340 
VRE - R R R S R Rheumatology (medical 1) 81 F Urine Ent.Facium 42295 
VRE - R R S S R CCU Heart 77 M Sputum Ent.Faecalis 9672 
VRE - R R R S R POST HSCT 18 M BAL Ent.Facium 52049 
VRE S R R R I R ICU 67 M Urine Ent.Facium 158651 
VRE - R S R I R Oral and Maxillofacial Surgery 57 M Wound Ent.Facium 157155 
VRE S R R R S R Urology 54 M Urine Ent.Facium 145513 
VRE S R R R S R ICU nerves 72 M Urine Ent.Facium 159316 
VRE S R R R S R Neurology 31 F Urine Ent.Facium 66085 
VRE S R R R S R Rheumatology 29 F Urine Ent.Facium 59106 
VRE - R R R S R ICU 64 F BAL Ent.Facium 72455 
VRE - R R R S R Glands medical 2)) 36 M Absess Ent.Facium 22898 
VRE S R S R S R ICU General 19 M Urine Ent.Facium 35937 
VRE S R R R S R Lung 82 M Urine Ent.Facium 35752 
VRE - R R R S R ICU 67 F Blood Ent.Facium 57964 
VRE S R S R S R Neurology 84 M Urine Ent.Facium 56970 
VRE - R R R I R ICU 82 F Blood Ent.Facium 115416 
VRE - R R R S R Urology 53 M Blood Ent.Facium 85528 
VRE - R R R I R BMT3 5 M Blood Ent.Facium 154481 
VRE S R R R S R Rheumatology (medical 1) 29 F Urine Ent.Facium 172201 
VRE S R R R S R POST HSCT 33 F Urine Ent.Facium 155971 
VRE - R R R S R Neurology surgery 65 F Urine Ent.Facium 173014 
VRE S R S R S  ICU (Heart) 78 M Urine Ent.Facium 163852 
VRE S R R R I R Neurology 57 M Urine Ent.Facium 156823 
VRE - R S S S R ICU 21 M Wound Ent.Facium 87302 
VRE - R R R I R Emergency Women 37 F Urine Ent.Facium 173414 
VRE S R S R S R ICU (Internal) 29 F Urine Ent.Facium 164022 
VRE - R R R S R ICU (Internal) 84 M Blood Ent.Facium 266513 
VRE - R R R S R Neurology 85 M Sputum Ent.Facium 244545 
VRE S R R R S R Lung 58 F Urine Ent.Facium 273767 
VRE - R R R I R ICU (General) 31 F Wound Ent.Facium 273596 
VRE - R R S S R Neurology 20 F Blood Ent.Facium 249612 
VRE S R R R I R ICU (General) 78 M Urine Ent.Facium 449632 
VRE - R R R S R ICU (General) 82 M BAL Ent.Facium 268143 
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VRE - R R R I R General Internal 76 F Blood Ent.Facium 248301 
VRE R R R R S R ICU 51 F Wound Ent.Facium 266397 
VRE - R S R S R ICU (General) 50 M BAL Ent.Facium 244608 
VRE - R R S I R General Internal 61 F Wound Ent.Facium 262197 
VRE - R R R S R ICU 60 M Urine Ent.Facium 244042 
VRE - R S R S R ICU 73 M Blood Ent.Facium 262177 
VRE S R R S S  Nephrology 77 F Urine Ent.Faecalis 252925 
VRE S R S R S R Blood 25 F Urine Ent.Faecalis 55966 
VRE S R R R S R ICU nerves 66 F Urine Ent.Facium 128910 
VRE  R S S S R Lung 36 M BAL Ent.Faecalis 123966 
VRE S R R S S R Rheumatology (medical 1) 32 F Urine Ent.Facium 138762 
VRE S R R R I R ICU 67 F Urine Ent.Facium 124097 
VRE S R S R I R Lung 78 F Urine Ent.Facium 389700 
VRE - S R S S R ICU 67 F Sputum Ent.Faecalis 124339 
VRE - R S R I R Internal ICU 69 F Blood Ent.Facium 7078 
VRE - R R R S R Digestive (medical 2) 54 F Blood Ent.Facium 53783 
VRE - S R S S R Nephrology 69 F Sputum Ent.Facium 48138 
VRE - R R R I R Blood 35 F Blood Ent.Facium 110840 
VRE S R S R S R ICU (General) 53 F Urine Ent.Facium 128391 
VRE - R R R S R Rheumatology 60 M BAL Ent.Facium 23182 
VRE - R R R S R Internal ICU 39 M Blood Ent.Facium 95966 
VRE R R S R S R Digestive (medical 2) 90 F Urine Ent.Facium 17472 
VRE S R R R S R NICU 55 days F Urine Ent.Facium 11346 
VRE - R S R S R Nephrology 75 F Sputum Ent.Facium 12684 
VRE S R R R S R OP 51 M Urine Ent.Facium 61017 
VRE R R R R I R Blood 41 M Urine Ent.Facium 391089 
VRE R R R R I R Internal ICU 70 F Urine Ent.Facium 428749 
VRE S R R R I R Nephrology 77 M urine Ent.Facium 25766 
VRE - R R R S R General Internal 80 F Blood Ent.Facium 398475 
VRE S R R R I R Nephrology 62 F Urine Ent.Facium 42043 
VRE - R R R S R ICU (General) 56 F Blood Ent.Facium 6062 
VRE - R R R S R ICU (General) 54 M Wound Ent.Facium 103787 
VRE - R R R S R POST HSCT 11 M Blood Ent.Facium 109402 
VRE S R R R S R Neurology 48 F Urine Ent.Facium 74756 
VRE S R GM/20 R S R BMT3 8 months F Urine Ent.Facium 95185 
Prevalence of Virulence Genes in E. faecium 
In 80 of the VRE isolates, asa1, gelE, and ESP genes were 
identified in 14(17/5%), 26/3 ( 21/80%), and 45 (36/80%), 
respectively. Moreover, in Ent. faecium strains, the ESP gene 
was the most prevalent factor and the asa1 gene has a low 
number, followed by the hyl gene. E. faecium carried ESP at a 
significantly higher frequency presented in the VRE strains (p 
< 0.001). The prevalence of the hly determinants in the E. 
faecium was 16 (20%) (P < 0.001). The presence of the asa1 
gene was also significant in the VRE strains (p < 0.001) as they 
were more commonly found in the VRE strains. 
Results of Statistical Analysis 
All the analyses were performed with the SPSS software 
(version 18.0) (USA). A chi-squared test was performed and P 
< 0.05 was considered statistically significant. 
Discussion 
Vancomycin-resistant Enterococci were introduced since 
1986. These microorganisms were first detected in the hospital 
in London (12). The urinary tract is the most common site of 
Enterococcal infections. Enterococci can, however, cause 
serious infections such as gallbladder inflammation, bile duct 
inflammation, peritonitis, septicemia, endocarditis, and 
meningitis (13, 14). Enterococci in the incidence of the 
nosocomial infection in the past two decades have gained the 
third place, followed by Escherichia coli and Staphylococcus 
aureus (14). Enterococci are responsible for 10% of hospital-
acquired infections in the USA (14). In urinary tract infections, 
Enterococci are constantly the second or the third most 
prevalent pathogens, bacteremia infections, wounds, and 
infections in hospitals (14). This pathogen accounted for 
approximately 16% of nosocomial urinary tract infections 
(14). 
In this study of 150 Enterococcus strains, 120 (80%) were 
identified as Ent. faecium isolates. To disagree with our 
study, Enterococcal faecalis is the most common isolate of 
Enterococci in most of the studies inside and outside the 
country in the clinical samples (15-17) . Studies by Ajay et al. 
and Sreeja et al. in India, in 2012, showed that the prevalence 
of the Enterococcus faecalisstrains were 55.5% and 76%, 
respectively (17). In other works by Fisher and Phillips in 2009 
(18) and Ukropina-Mihajlovic in 2012 (19) reported that the 
situation of Enterococcus faecalis were high (3). In recent 
years, an increase in the rate of Enterococcus faecium 
compared to Ent. faecium is observed. In our study, the 
frequency of Vancomycin-resistance Enterococci was 53/3% 
(80/150). Dissimilar to our study, Deshpande et al. showed the 
prevalence of Vancomycin-resistance as 19.6% (4, 20-22) . In 
disagreement with our study, Bhatt et al. (23) and all the other 
studies from India have stated a prevalence of approximately 
10%. 
Exposed to different antibiotics, including Vancomycin, 
cephalosporin, augmenting Vancomycin’s selective pressure 
can be one of the main reasons for a high prevalence of 
Vancomycin-resistance among Enterococci (24). In a study, 
Bhatt et al. reported that only 13 isolates showed a high-level 
of resistance to Vancomycin in which one gene was extant in 
these 13 isolates (24). Among the VRE strains, the VanA 
phenotype is the most common genotype, particularly in 
isolates with a high-level resistance to both Vancomycin and 
teicoplanin. Similar to our study, Praharaj et al. presented that 
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the VanA phenotype was detected in a high number of all the 
VRE isolates (87.5%) (24). According to the typing results of 
the genotypes, among the VRE strains found in Shariati 
Hospital in Tehran, genotype VanB was the second most 
common genotype. In agreement with our results, Nasaj et al. 
showed that two VRE isolates (3.3%) carried the VanB gene 
(10). Therefore, in Tehran hospitals, conventional antibiotics 
cannot be considered as suitable treatments for Vancomycin-
resistant strains. However, there was no resistance to a new 
antibiotic, such as linezolid, which could be an appropriate 
therapeutic choice. New antibiotics such as linezolid, 
tigecycline, and daptomycin can be used as alternatives for the 
treatment of Enterococcal infections with multiple-drug 
resistance. 
It should be pointed out that among the various antimicrobials 
available and assessed for the treatment of serious infections 
with Vancomycin-resistant enterococci, linezolid is very 
effective in our hospitals. In agreeing with our study, in recent 
years, increasing high-level resistance to aminoglycosides, 
penicillin, and ampicillin has been particularly revealed in 
Vancomycin-resistant Ent. faecium isolates (9, 25). With 
respect to the results in our hospital, linezolid was prescribed 
as a first-choice in patients infected by VRE Enterococci while 
we faced with increases in the prevalence of intermediate 
linezolid resistance. Recently, outbreaks related to the VRE 
Ent. faecium infection in patients without prior exposure to 
linezolid have been described by Rahim et al. (26). In addition, 
the prevalence of multiple clones of linezolid-resistant E.f 
from the other parts of the world have been reported (27). In 
this situation in our hospitals, the evaluation all the VRE 
isolates for susceptibility, following on to appropriate 
infection-control measures, and to emphasize the significance 
of using linezolid with caution is necessary. 
The ESP determinants contribute to the biofilm formation and 
the interface with primary surfaces (4, 28) . In disagreement 
with our study, Vankerckhoven et al. (12) described that the 
gelE and asa1 genes in the European E. faecium isolates were 
not identified. This results are approximately agreed on in the 
reports that are mentioned in the presence of one or more of 
these genes by other researchers (12, 29, 30) . Consenting to 
our study, Comerlato et al. (in Brazil) indicated that asa1, gelE, 
and ESP genes were detected in 38%, 60%, and 76%, 
respectively, with all the isolates, respectively (2). This 
difference can only be due to the isolates of Ent. faecium that 
have been studied in our study; in other research, however, the 
prevalence of both Enterococcal groups had been investigated. 
The ESP determinants supported the primary attachment and 
the biofilm formation in the bacteria to the urinary tract and 
polyvinyl chloride plastic (28). Our findings appear to be well-
supported by Arshadi et al. (31), who showed a high number 
of ESP-positive Ent. faecium compared with asa1 and gelE 
genes with low frequencies. The high prevalence of the ESP 
gene in Ent. faecium indicated the important role of the gene 
in the virulence process (32). 
The virulence gene ESP is related to hospital outbreaks 
throughout the world and a significant feature of clonal-
complex 17 (CC17) (33). In the present study, the pattern of 
antimicrobial resistance in the Enterococcus strains was not 
related to the presence or the absence of virulence genes (P < 
0.05). Hyl (hyaluronidase), encoded by chromosomal DNA, 
has been associated with significant tissue damage by 
degradative enzyme activity (18, 34). We detect the hyl gene 
among 16 (20%) the VRE Ent. faecium isolates. The hyl gene 
was identified in 16 (20%) of the 80 Ent. faecium isolates 
collected in Shariati Hospital, while our finding is in contrast 
to the work of Rice et al. (3%) (35). Moreover, in contrast to 
our study prevalence of the hyl gene in VREEnt. faecium 
isolates, it was more widespread among the United Kingdom 
isolates (71%) (36). 
 
Conclusion 
This study illustrates the Ent. faecium isolates had a high level 
frequency in our hospital. Furthermore, in the Shariati 
hospital, we were faced with high rate of VRE isolates in Ent. 
faecium, with VanA-positive Ent. faecium isolates. With 
increasing resistance of the VRE strains to linezolid, we will 
encounter serious challenges in treating VRE patients in the 
future. In addition, an interesting finding from the present 
study was the higher spreading rates of ESP and hly 
among Ent. faecium spp. In such cases, the use of policy and 
regular efficient surveillance in order to control of VRE Ent. 
faecium strain in our hospitals is important during 
emergencies. 
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